AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23583001 — intervention group
Group type: COMPARATOR
Intervention: Control group with no planned reminiscence treatment
Number of subjects: 82
Study 21558577 — intervention group
Group type: COMPARATOR
Intervention: 6 mg/kg caffeine (6CAF)
Number of subjects: 12
Study 21558577 — intervention group
Group type: COMPARATOR
Intervention: 2 mg/kg caffeine (2CAF)
Number of subjects: 12
Study 19705680 — intervention group
Group type: EXPERIMENTAL
Intervention: Free plus guide mapping
Number of subjects: 82
Study 19705680 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 82
Study 16035095 — intervention group
Group type: EXPERIMENTAL
Intervention: rFVIIa 60 or 120 microg/kg
Number of subjects: 182
Study 16035095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study 12400822 — intervention group
Group type: EXPERIMENTAL
Intervention: Active coronary perfusion (ACP)
Number of subjects: 151
Study 12400822 — intervention group
Group type: COMPARATOR
Intervention: Passive coronary perfusion (PCP)
Number of subjects: 151
Study 12400822 — intervention group
Group type: COMPARATOR
Intervention: No coronary perfusion (NCP)
Number of subjects: 151
Study 10787647 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin‐impregnated curtains
Number of subjects: 0
Study 7805231 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking (current smokers)
Number of subjects: 1619
Study 7805231 — intervention group
Group type: COMPARATOR
Intervention: Non-smoking (nonsmokers)
Number of subjects: 1619
Study 2135223 — intervention group
Group type: EXPERIMENTAL
Intervention: Telenzepine (5 mg, single oral dose)
Number of subjects: 18
Study 2135223 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol (2 puffs)
Number of subjects: 18
Study 389336 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexabrix (32% iodine) - sodium and meglumine salts of ioxaglic acid
Number of subjects: 33
Study 389336 — intervention group
Group type: COMPARATOR
Intervention: Conray 280 (28% iodine) - meglumine iothalamate
Number of subjects: 33
Study 31382292 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported swollen joints (SJ)
Number of subjects: 80
Study 31382292 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported tender joints (TJ)
Number of subjects: 80
Study 31382292 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically examined swollen joints (SJ)
Number of subjects: 80
Study 31382292 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically examined tender joints (TJ)
Number of subjects: 80
Study 31382292 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical examination and US findings
Number of subjects: 80
Study 30844672 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmation intervention prior to informing about chemotherapy-related cognitive problems
Number of subjects: 90
Study 30844672 — intervention group
Group type: EXPERIMENTAL
Intervention: Information about chemotherapy-related cognitive problems
Number of subjects: 90
Study 30844672 — intervention group
Group type: COMPARATOR
Intervention: No-information control
Number of subjects: 90
Study 27285541 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsurgical resection of cerebral AVMs
Number of subjects: 288
Study 25816807 — intervention group
Group type: EXPERIMENTAL
Intervention: everolimus (trough concentration 3‐8 ng/mL or 6‐12 ng/mL) with reduced cyclosporine
Number of subjects: 833
Study 25816807 — intervention group
Group type: COMPARATOR
Intervention: mycophenolic acid (MPA) with standard cyclosporine
Number of subjects: 833
Study 25816807 — intervention group
Group type: EXPERIMENTAL
Intervention: everolimus (trough concentration 3‐8 ng/mL or 6‐12 ng/mL)
Number of subjects: 833
Study 23389072 — intervention group
Group type: EXPERIMENTAL
Intervention: TEP
Number of subjects: 314
Study 23389072 — intervention group
Group type: COMPARATOR
Intervention: TAPP
Number of subjects: 314
Study 21411700 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquamantys 6.0 bipolar sealer
Number of subjects: 140
Study 21411700 — intervention group
Group type: COMPARATOR
Intervention: Standard Bovie electrocautery
Number of subjects: 140
Study 19392811 — intervention group
Group type: EXPERIMENTAL
Intervention: Massed group CBT (daily 4‐h sessions in week 1, two 2‐h sessions in week 2 and one 2‐h session in week 3)
Number of subjects: 39
Study 19392811 — intervention group
Group type: COMPARATOR
Intervention: Traditional spaced weekly group CBT (13 consecutive, weekly 2‐h sessions)
Number of subjects: 39
Study 17217576 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose supplements (4 x 250 ml per day, providing 1800 kJ per day)
Number of subjects: 133
Study 17217576 — intervention group
Group type: COMPARATOR
Intervention: Sweetener supplements (4 x 250 ml per day, providing 67 kJ per day)
Number of subjects: 133
Study 17217576 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose supplements
Number of subjects: 133
Study 17217576 — intervention group
Group type: COMPARATOR
Intervention: Sweetener supplements
Number of subjects: 133
Study 15051557 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediolateral episiotomy
Number of subjects: 519
Study 15051557 — intervention group
Group type: COMPARATOR
Intervention: Control (intact perineum or spontaneous lacerations)
Number of subjects: 519
Study 11451134 — intervention group
Group type: EXPERIMENTAL
Intervention: Cementless fixation
Number of subjects: 67
Study 11451134 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid fixation
Number of subjects: 67
Study 11451134 — intervention group
Group type: COMPARATOR
Intervention: Cementless and Hybrid fixation
Number of subjects: 67
Study 9669472 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine 90 mg daily for 12 weeks
Number of subjects: 100
Study 9669472 — intervention group
Group type: COMPARATOR
Intervention: No drug (control)
Number of subjects: 100
Study 7604632 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-closure of visceral peritoneums (n = 91)
Number of subjects: 240
Study 7604632 — intervention group
Group type: COMPARATOR
Intervention: Peritoneal suturing (Control group, n = 149)
Number of subjects: 240
Study 3394823 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine (40 ng.kg‐1.min‐1 iv)
Number of subjects: 28
Study 3394823 — intervention group
Group type: COMPARATOR
Intervention: Placebo (glucose)
Number of subjects: 28
Study 29631559 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline subsistence difficulties (none, low, high)
Number of subjects: 306
Study 29216962 — intervention group
Group type: EXPERIMENTAL
Intervention: Miners who worked for three consecutive days
Number of subjects: 94
Study 29216962 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 94
Study 29216962 — intervention group
Group type: EXPERIMENTAL
Intervention: Lead exposure
Number of subjects: 94
Study 23549654 — intervention group
Group type: EXPERIMENTAL
Intervention: PriMa program (n=1553 girls)
Number of subjects: 2086
Study 23549654 — intervention group
Group type: EXPERIMENTAL
Intervention: Torera program (n=256 boys, 277 girls)
Number of subjects: 2086
Study 24168756 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone plus salmeterol
Number of subjects: 45
Study 24168756 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone
Number of subjects: 45
Study 24168756 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone (alone or in combination with salmeterol)
Number of subjects: 45
Study 24168756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 24168756 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone alone
Number of subjects: 45
Study 19800262 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucocorticoids
Number of subjects: 40
Study 19800262 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular glucocorticoid injections
Number of subjects: 40
Study 18241753 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month supervised exercise program (TPAD-IC)
Number of subjects: 21
Study 18241753 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy (CPAD-IC)
Number of subjects: 21
Study 18241753 — intervention group
Group type: COMPARATOR
Intervention: Age and mass matched controls (CON)
Number of subjects: 21
Study 16151785 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2% (Alphagan)
Number of subjects: 36
Study 16151785 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 12445849 — intervention group
Group type: EXPERIMENTAL
Intervention: Undercorrected group (blurred by approximately +0.75 D)
Number of subjects: 94
Study 12445849 — intervention group
Group type: COMPARATOR
Intervention: Fully corrected control group
Number of subjects: 94
Study 10321912 — intervention group
Group type: EXPERIMENTAL
Intervention: Parallel group (43 specimens)
Number of subjects: 23
Study 10321912 — intervention group
Group type: COMPARATOR
Intervention: Perpendicular group (39 specimens)
Number of subjects: 23
Study 8881869 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide infusion (0.5, 1, 2, 5 pmol.kg‐1.min‐1)
Number of subjects: 10
Study 8881869 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide infusion (5 pmol.kg‐1.min‐1)
Number of subjects: 10
Study 8881869 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% (w/v) saline)
Number of subjects: 10
Study 2012585 — intervention group
Group type: COMPARATOR
Intervention: Control group (suitably matched controls)
Number of subjects: 0
Study 6781657 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled verapamil (estimated dose 3 mg)
Number of subjects: 10
Study 6781657 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (estimated dose 12 mg)
Number of subjects: 10
Study 6781657 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 10
Study 29788198 — intervention group
Group type: EXPERIMENTAL
Intervention: VTE chemoprophylaxis initiated in 412 patients (82.4%)
Number of subjects: 500
Study 29788198 — intervention group
Group type: EXPERIMENTAL
Intervention: VTE chemoprophylaxis initiated before VTE diagnosis in 401 patients (80.2%)
Number of subjects: 500
Study 29788198 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection within 30 days
Number of subjects: 500
Study 29788198 — intervention group
Group type: EXPERIMENTAL
Intervention: Starting VTE chemoprophylaxis after 72 hours
Number of subjects: 500
Study 29788198 — intervention group
Group type: EXPERIMENTAL
Intervention: VTE chemoprophylaxis in IVH
Number of subjects: 500
Study 27232556 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepping exercise group (SG)
Number of subjects: 42
Study 27232556 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 42
Study 25873132 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide (long-acting release, 60 mg injection)
Number of subjects: 34
Study 25873132 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 34
Study 23347140 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography pulmonary angiography scan (CT-scan)
Number of subjects: 347
Study 23347140 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfusion scintigraphy scan (Q-scan)
Number of subjects: 347
Study 23347140 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin with vitamin K antagonist (VKA)
Number of subjects: 347
Study 23347140 — intervention group
Group type: COMPARATOR
Intervention: Rivaroxaban
Number of subjects: 347
Study 21414740 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX4 regimen (oxaliplatin 85 mg/m(2) as a 2‐h infusion on day 1, leucovorin 200 mg/m(2)/d, 5‐fluorouracil 400 mg/m(2)/d bolus and 600 mg/m(2)/d infusion for 2 consecutive days every 2 weeks)
Number of subjects: 80
Study 21414740 — intervention group
Group type: COMPARATOR
Intervention: LV5Fu2 regimen (leucovorin 200 mg/m(2)/d, 5‐fluorouracil 400 mg/m(2)/d bolus and 600 mg/m(2)/d infusion for 2 consecutive days every 2 weeks)
Number of subjects: 80
Study 19707146 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonographic measurement of antral area after 12 h fasting
Number of subjects: 22
Study 19707146 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonographic measurement of antral area 2 h after ingestion of 200 ml of nonclear liquids
Number of subjects: 22
Study 19707146 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonographic measurement of antral area 2 h after a solid meal of 300 kcal
Number of subjects: 22
Study 17689023 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine monotherapy, 1,000 mg/m2 twice daily for 2 weeks, followed by capecitabine (650-1,000 mg/m2 orally twice daily 5 days/week) combined with radiotherapy for 5 weeks.
Number of subjects: 66
Study 17689023 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine-based chemoradiotherapy
Number of subjects: 66
Study 15279529 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 sessions of motivational enhancement therapy (MET)
Number of subjects: 450
Study 15279529 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 sessions of multicomponent therapy (including MET, cognitive-behavioral therapy, and case management)
Number of subjects: 450
Study 15279529 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment control (DTC)
Number of subjects: 450
Study 11568588 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutathione (GSH) treatment, 600 mg in 4 mL saline per day, administered via nasal aerosol in five 2-minute sessions every 3 or 4 waking hours for 2 weeks.
Number of subjects: 60
Study 11568588 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4 mL saline per day), administered via nasal aerosol in the same manner as GSH treatment.
Number of subjects: 60
Study 10705020 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 8 Gy fraction
Number of subjects: 90
Study 10705020 — intervention group
Group type: COMPARATOR
Intervention: 20 Gy in 5 fractions
Number of subjects: 90
Study 10705020 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms combined
Number of subjects: 90
Study 9272770 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (L-CHO)
Number of subjects: 8
Study 1279497 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg flutamide for three months
Number of subjects: 23
Study 1279497 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg flutamide for three months
Number of subjects: 23
Study 1279497 — intervention group
Group type: COMPARATOR
Intervention: Both doses (500 mg and 750 mg)
Number of subjects: 23
Study 2870833 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 10
Study 2870833 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 10
Study 2870833 — intervention group
Group type: COMPARATOR
Intervention: Pindolol
Number of subjects: 10
Study 29885369 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocannabinoidome lipid mediators (AEA, OEA, PEA, SEA, 2-AG)
Number of subjects: 104
Study 29885369 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocannabinoidome lipid mediators (2-AG)
Number of subjects: 104
Study 29885369 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocannabinoidome lipid mediators (AEA)
Number of subjects: 104
Study 29885369 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects (N=116)
Number of subjects: 104
Study 27091583 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy massage
Number of subjects: 51
Study 27091583 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflexology
Number of subjects: 51
Study 27091583 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 51
Study 24717147 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode Laser (DL) pulpotomy
Number of subjects: 120
Study 24717147 — intervention group
Group type: COMPARATOR
Intervention: Formocresol (FC) pulpotomy
Number of subjects: 120
Study 24717147 — intervention group
Group type: COMPARATOR
Intervention: Ferric Sulphate (FS) pulpotomy
Number of subjects: 120
Study 22696517 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation (CA)
Number of subjects: 52
Study 22696517 — intervention group
Group type: COMPARATOR
Intervention: Conservative therapy (pharmacological)
Number of subjects: 52
Study 20386884 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 20 mg
Number of subjects: 14
Study 20386884 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 40 mg
Number of subjects: 14
Study 20386884 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 20386884 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 20 mg + 0.0001 mg NTX
Number of subjects: 14
Study 20386884 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 20 mg + 0.001 mg NTX
Number of subjects: 14
Study 20386884 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 40 mg + 0.0001 mg NTX
Number of subjects: 14
Study 20386884 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 40 mg + 0.001 mg NTX
Number of subjects: 14
Study 18541560 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient-fortified seasoning powder (5 mg Fe, 5 mg Zn, 50 mug I, 270 mug vitamin A per serving) consumed with school lunch 5 days/week
Number of subjects: 569
Study 18541560 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fortification)
Number of subjects: 569
Study 15741775 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 5 microg via Certihaler
Number of subjects: 77
Study 15741775 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 10 microg via Certihaler
Number of subjects: 77
Study 15741775 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 15 microg via Certihaler
Number of subjects: 77
Study 15741775 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 30 microg via Certihaler
Number of subjects: 77
Study 15741775 — intervention group
Group type: COMPARATOR
Intervention: Formoterol 12 microg via Aerolizer
Number of subjects: 77
Study 15741775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 11921451 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal history of asthma
Number of subjects: 208
Study 11921451 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitization to house dust mites
Number of subjects: 208
Study 11921451 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitization to Alternaria
Number of subjects: 208
Study 11921451 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin test reactivity (STR) to house dust mite
Number of subjects: 208
Study 11921451 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin test reactivity (STR) to cat dander
Number of subjects: 208
Study 11921451 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal history of eczema
Number of subjects: 208
Study 11921451 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin test reactivity (STR) to dog dander
Number of subjects: 208
Study 11921451 — intervention group
Group type: COMPARATOR
Intervention: Current wheezing
Number of subjects: 208
Study 10444434 — intervention group
Group type: EXPERIMENTAL
Intervention: T(3) (50 micrograms per day)
Number of subjects: 14
Study 10444434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 7483181 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical strategies with low to moderate doses of medication titrated over 12 weeks
Number of subjects: 0
Study 7483181 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization strategies
Number of subjects: 0
Study 2033109 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 17
Study 2033109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 30134739 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial rebreathing device
Number of subjects: 11
Study 30134739 — intervention group
Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 11
Study 27229348 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine 50 mg/day
Number of subjects: 24
Study 27229348 — intervention group
Group type: COMPARATOR
Intervention: Melatonin 10 mg/day
Number of subjects: 24
Study 27229348 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch from melatonin to agomelatine
Number of subjects: 24
Study 24612998 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based treadmill training (14 weeks, 3 sessions per week, 40 min at 55-70% peak heart rate)
Number of subjects: 60
Study 24612998 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based treadmill training
Number of subjects: 60
Study 24612998 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training program)
Number of subjects: 60
Study 22483162 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 248
Study 22483162 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 248
Study 20499349 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of zoledronate
Number of subjects: 50
Study 20499349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 18949107 — intervention group
Group type: EXPERIMENTAL
Intervention: Sputum strategy (SS)
Number of subjects: 39
Study 18949107 — intervention group
Group type: COMPARATOR
Intervention: Clinical strategy (CS)
Number of subjects: 39
Study 15721729 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant positive airway pressure (12 ± 2 cm H(2)O)
Number of subjects: 9
Study 15721729 — intervention group
Group type: COMPARATOR
Intervention: Pressure support (3.1 ± 0.3 cm H(2)O)
Number of subjects: 9
Study 12755522 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis by Behvarzes
Number of subjects: 2000
Study 12755522 — intervention group
Group type: COMPARATOR
Intervention: Diagnosis by specialists (obstetricians)
Number of subjects: 2000
Study 11011338 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose warfarin (1 to 4 mg/d)
Number of subjects: 80
Study 11011338 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacin
Number of subjects: 80
Study 11011338 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant vitamin treatment
Number of subjects: 80
Study 8803378 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release morphine (SRM) administered at a 12‐hr interval
Number of subjects: 44
Study 8803378 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release morphine (SRM)
Number of subjects: 44
Study 1454315 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 0.25% or 0.5% twice daily
Number of subjects: 189
Study 1454315 — intervention group
Group type: COMPARATOR
Intervention: Pilocarpine 2% or 4% four times daily
Number of subjects: 189